New Serological Markers for Eosinophilic Esophagitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The eosinophilic esophagitis (EE) is chronic inflammatory and immunological disease. The diagnosis of EE is based upon large numbers of eosinophils in the esophagus on histopathologic examination (> 20 eosinophils per high powered field in at least one specimen) despite acid suppression with a Proton-Pump-Inhibitor (PPI) for at least two weeks.
There are no diagnostic serological markers for EE so far, so that the purpose of the study is to investigate serological markers which are established in other allergic diseases.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Monther Bajbouj, MD
- Phone Number: +49-89-41402450
- Email: monther.bajbouj@lrz.tum.de
Study Contact Backup
- Name: Christoph Schlag, MD
- Phone Number: +49-89-41402450
- Email: Christoph.Schlag@lrz.tum.de
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 81675
- Recruiting
- II. Medical Department, Technical University Munich
-
Contact:
- Monther Bajbouj, MD
- Phone Number: 0049-89-41400
- Email: monther.bajbouj@lrz.tum.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- histopathological defined eosinophilic esophagitis
- Age: 18-80
Exclusion Criteria:
- missing consent form
- contraindications for performing esophagogastroscopy/taking biopsies of the esophagus
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
eosinophilic esophagitis
patients with histopathological defined eosinophilic esophagitis
|
Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Monther Bajbouj, MD, Technical University of Munich, 2nd Medical Department
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Hypersensitivity, Immediate
- Hypersensitivity
- Eosinophilia
- Leukocyte Disorders
- Hematologic Diseases
- Esophageal Diseases
- Gastroenteritis
- Esophagitis
- Eosinophilic Esophagitis
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Dermatologic Agents
- Respiratory System Agents
- Anti-Asthmatic Agents
- Bronchodilator Agents
- Anti-Allergic Agents
- Fluticasone
Other Study ID Numbers
Other Study ID Numbers
- 2011_0023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.